Association among metabolic syndrome, inflammation, and survival in prostate cancer.

•MS is an important condition to be investigated in mCRPC treated with abiraterone or enzalutamide.•Inflammation may be associated with MS, and both can favor tumor proliferation and progression.•Identification of MS before starting therapy might contribute to better prognostication of mCRPC.•MS may help to identify a high-risk prognostic group that needs intervention for metabolic risk factors.•Larger and prospective trials are warranted to establish the exact role of MS for CRPC management.